Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging

Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Prospective Multicenter Clinical Trial With Multimodality MR Imaging

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03102203

Enrollment

350

Registered

2017-04-05

Start date

2016-06-08

Completion date

2018-12-31

Last updated

2017-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Brief summary

To evaluate the efficacy of multi-modality magnetic resonance quantitative parameters in evaluating the treatment effects of high-grade gliomas, and to provide new biomarkers for the establishment of new diagnostic criteria for the identification of true and pseudoprogression of high-grade gliomas.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Patients with high-grade gliomas confirmed by pathology and have not been treated with concurrent chemoradiotherapy; 2. Written informed consent is obtained.

Exclusion criteria

1. Patients not suitable for enhanced MRI scanning of patients; 2. Patients who have not finished follow-up concurrent chemoradiotherapy or MR scanning.

Design outcomes

Primary

Measure	Time frame	Description
Ktrans	baseline	The volume transfer constant in dynamic contrast-enhanced MR Imaging

Countries

China

Contacts

Primary ContactYuan Xie, Master

cheryl050914@163.com+86 13584099838

Outcome results